Role of p53β in the inhibition of proliferation of gastric cancer cells expressing wild-type or mutated p53

Ji,Wansheng; Ma,Jingrong; Zhang,Hongmei; Zhong,Hua; Li,Lei; Ding,Na; Jiao,Jianxin; Gao,Zhixing

doi:10.3892/mmr.2015.3370

Role of p53β in the inhibition of proliferation of gastric cancer cells expressing wild-type or mutated p53

Authors:
- Wansheng Ji
- Jingrong Ma
- Hongmei Zhang
- Hua Zhong
- Lei Li
- Na Ding
- Jianxin Jiao
- Zhixing Gao
View Affiliations

Affiliations: Department of Gastroenterology, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261031, P.R. China, Graduate School of Weifang Medical University, Weifang, Shandong 261031, P.R. China
Published online on: February 18, 2015 https://doi.org/10.3892/mmr.2015.3370
Pages: 691-695

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

p53 is a tumor suppressor gene whose mutation is highly associated with tumorigenesis. The present study investigated the role of p53β in the inhibition of proliferation of gastric cancer cell lines expressing wild‑type or mutated p53. Wild‑type p53 is expressed in MKN45 cells, but deleted in KATOIII cells, whereas mutated p53 is expressed in SGC7901 cells. The mRNA expression levels of p53β and Δ133p53 were detected in MKN45, SGC‑7901 and KATOIII gastric cancer cell lines using nested polymerase chain reaction (PCR). The mRNA expression levels of p53, p53β and B‑cell lymphoma 2‑associated X protein (Bax) were detected in the MKN45 and SGC‑7901 cells following treatment with cisplatin by reverse transcription‑PCR. The inhibition of cellular proliferation following treatment with cisplatin was measured by MTT assay. The results of the present study demonstrated that both p53β and Δ133p53 mRNA were expressed in the MKN45 cells, whereas only p53β mRNA was expressed in the SGC7901 cells. No expression of p53β or Δ133p53 mRNA was detected in the KATOIII cells. Following treatment with cisplatin, the number of both MKN45 and SGC‑7901 cells was significantly reduced (P<0.001). In the MKN45 cells, p53β, p53 and Bax mRNA expression levels gradually increased with the dose of cisplatin, and the expression of p53β was positively correlated with the expression of p53 (tr=6.358, P<0.05) and Bax (tr=8.023, P<0.05). In the SGC‑7901 cells, the expression levels of p53β, p53 and Bax mRNA did not alter with the dose of cisplatin, and the expression of p53β was positively correlated to the expression of p53 (tr=26.41, P<0.01) but not that of Bax. The present study identified the different roles of the p53β isoform in gastric cancer cells with different p53 backgrounds. Enhanced knowledge regarding the p53 status is required for the development of specific biological therapies against gastric cancer.

View Figures

View References

1	Tsui KC, Chiang TH, Wang JS, et al: Flavonoids from Gynostemma pentaphyllum exhibit differential induction of cell cycle arrest in H460 and A549 cancer cells. Molecules. 19:17663–17681. 2014. View Article : Google Scholar : PubMed/NCBI
2	Liu W, Lu X, He G, et al: Protective roles of Gadd45 and MDM2 in blueberry anthocyanins mediated DNA repair of fragmented and non-fragmented DNA damage in UV-irradiated HepG2 cells. Int J Mol Sci. 14:21447–21462. 2013. View Article : Google Scholar : PubMed/NCBI
3	Yasui Y, Hosokawa M, Sahara T, et al: Bitter gourd seed fatty acid rich in 9c, 11t, 13t-conjugated linolenic acid induces apoptosis and up-regulates the GADD45, p53 and PPARgamma in human colon cancer Caco-2 cells. Prostaglandins Leukot Essent Fatty Acids. 73:113–119. 2005. View Article : Google Scholar : PubMed/NCBI
4	Aoubala M, Murray-Zmijewski F, Khoury MP, et al: p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage. Cell Death Differ. 18:248–258. 2011. View Article : Google Scholar :
5	Sauer M, Bretz AC, Beinoraviciute-Kellner R, et al: C-terminal diversity within the p53 family accounts for differences in DNA binding and transcriptional activity. Nucleic Acids Res. 36:1900–1912. 2008. View Article : Google Scholar : PubMed/NCBI
6	Courtois S, Verhaegh G, North S, et al: DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene. 21:6722–6728. 2002. View Article : Google Scholar : PubMed/NCBI
7	Chan WM and Poon RY The p53 Isoform Deltap53 lacks intrinsic transcriptional activity and reveals the critical role of nuclear import in dominant-negative activity. Cancer Res. 67:1959–1969. 2007. View Article : Google Scholar
8	Marcel V, Perrier S, Aoubala M, et al: Δ160p53 is a novel N-terminal p53 isoform encoded by Δ133p53 transcript. FEBS Lett. 584:4463–4468. 2010. View Article : Google Scholar : PubMed/NCBI
9	Song W, Huo SW, Lü JJ, et al: Expression of p53 isoforms in renal cell carcinoma. Chin Med J (Engl). 122:921–926. 2009.
10	Bourdon JC, Khoury MP, Diot A, et al: p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res. 13:R72011. View Article : Google Scholar
11	Chambers SK and Martinez JD: The significance of p53 isoform expression in serous ovarian cancer. Future Oncol. 8:683–686. 2012. View Article : Google Scholar : PubMed/NCBI
12	Philipova T, Baryawno N, Hartmann W, et al: Differential forms of p53 in medulloblastoma primary tumors, cell lines and xenografts. Int J Oncol. 38:843–849. 2011.
13	Goldschneider D, Horvilleur E, Plassa LF, et al: Expression of C-terminal deleted p53 isoforms in neuroblastoma. Nucleic Acids Res. 34:5603–5612. 2006. View Article : Google Scholar : PubMed/NCBI
14	Avery-Kiejda KA, Zhang XD, Adams LJ, et al: Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin Cancer Res. 14:1659–1668. 2008. View Article : Google Scholar : PubMed/NCBI
15	Boldrup L, Bourdon JC, Coates PJ, Sjöström B and Nylander K: Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur J Cancer. 43:617–623. 2007. View Article : Google Scholar : PubMed/NCBI
16	Ånensen N, Hjelle SM, Van Belle W, et al: Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene. 31:1533–1545. 2012. View Article : Google Scholar
17	Bourdon JC, Fernandes K, Murray-Zmiewski F, et al: p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 19:2122–2137. 2005. View Article : Google Scholar : PubMed/NCBI
18	Bernard H, Garmy-Susini B, Ainaoui N, et al: The p53 isoform, Δ133p53α, stimulates angiogenesis and tumour progression. Oncogene. 32:2150–2160. 2013. View Article : Google Scholar
19	Sigal A and Rotter V: Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 60:6788–6793. 2000.
20	Terrier O, Marcel V, Cartet G, et al: Influenza A viruses control expression of proviral human p53 isoforms p53β and Delta133p53α. J Virol. 86:8452–8460. 2012. View Article : Google Scholar : PubMed/NCBI
21	Campbell HG, Slatter TL, Jeffs A, et al: Does Δ133p53 isoform trigger inflammation and autoimmunity? Cell Cycle. 11:446–450. 2012. View Article : Google Scholar : PubMed/NCBI
22	Berglind H, Pawitan Y, Kato S, Ishioka C and Soussi T: Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination. Cancer Biol Ther. 7:699–708. 2008. View Article : Google Scholar : PubMed/NCBI
23	Hofstetter G, Berger A, Schuster E, et al: Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer. Br J Cancer. 105:1593–1599. 2011. View Article : Google Scholar : PubMed/NCBI
24	Solomon H, Sharon M and Rotter V: Modulation of alternative splicing contributes to cancer development: focusing on p53 isoforms, p53β and p53γ. Cell Death Differ. 21:1347–1349. 2014. View Article : Google Scholar : PubMed/NCBI
25	Marcel V, Fernandes K, Terrier O, Lane DP and Bourdon JC: Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response. Cell Death Differ. 21:1377–1387. 2014. View Article : Google Scholar : PubMed/NCBI
26	Hofstetter G, Berger A, Berger R, et al: The N-terminally truncated p53 isoform Δ40p53 influences prognosis in mucinous ovarian cancer. Int J Gynecol Cancer. 22:372–379. 2012. View Article : Google Scholar : PubMed/NCBI
27	Graupner V, Schulze-Osthoff K, Essmann F and Jänicke RU: Functional characterization of p53beta and p53gamma, two isoforms of the tumor suppressor p53. Cell Cycle. 8:1238–1248. 2009. View Article : Google Scholar : PubMed/NCBI
28	Camus S, Ménendez S, Fernandes K, et al: The p53 isoforms are differentially modified by Mdm2. Cell Cycle. 11:1646–1655. 2012. View Article : Google Scholar : PubMed/NCBI
29	Marine JC and Lozano G: Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ. 17:93–102. 2010. View Article : Google Scholar